Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574831 | 1.00 | FFAR1 (0.41) | FFAR1IDH1MAOBLTB4RLTB4R2 | |
| SCHEMBL30574747 | 0.89 | FFAR1 (0.43) | FFAR1IDH1LTB4RLTB4R2HPGD | |
| SCHEMBL25385791 | 0.89 | FFAR1 (0.43) | FFAR1IDH1LTB4RLTB4R2HPGD | |
| SCHEMBL30574945 | 0.83 | LTB4R (0.45) | FFAR1LTB4RLTB4R2HPGDSMN1; SMN2 | |
| SCHEMBL25384951 | 0.83 | LTB4R (0.45) | FFAR1LTB4RLTB4R2HPGDSMN1; SMN2 | |
| SCHEMBL31562487 | 0.83 | MEN1 (0.43) | MAOBHPGDSMN1; SMN2MAPT | |
| SCHEMBL25385031 | 0.82 | LTB4R (0.55) | FFAR1LTB4RLTB4R2SMN1; SMN2 | |
| SCHEMBL30574892 | 0.82 | LTB4R (0.55) | FFAR1LTB4RLTB4R2SMN1; SMN2 | |
| SCHEMBL25385433 | 0.80 | MAOB (0.37) | MAOBHPGDSMN1; SMN2MAPT | |
| SCHEMBL30574828 | 0.80 | MAOB (0.37) | MAOBHPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | FFAR1 3401/4885IDH1 517/4885MAOB 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.